Prognostic Role of P53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2023 Nov 23

PMID 37995311

Authors

Gerti Dajti

Margherita Serra

Giovanni Cisternino

Claudio Ceccarelli

Alice Pellegrini

Marica Melina

Antonio De Leo

Donatella Santini

Mario Taffurelli

Simone Zanotti

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer.

Methods: Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%), low (0.1%-49%), and high (≥50%) p53 expression.

Results: A total of 1387 patients were included in the study with a median follow-up of 86 months. After adjusting for age, size, node status, lymphovascular invasion, progesterone, and Ki67 expression, only null p53 immunophenotype was associated with worse disease-free survival (DFS) (OR 1.74, 95% IC, 1.11-2.71, P = .015) and distant recurrence-free survival (DRFS) (OR 1.73, 95% IC, 1.04-2.90, P = .036). Null p53 impacted significantly DFS and DRFS also in patients with early breast cancer.

Conclusions: p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer.

Citing Articles

Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations.

Armbruster H, Schotte T, Gotting I, Overkamp M, Granai M, Volmer L Virchows Arch. 2024; 485(4):631-642.

PMID: 39191994 PMC: 11522169. DOI: 10.1007/s00428-024-03897-3.

References

Kim H, Yom C, Kim H, Lee J, Sohn J, Kim J . Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy. Breast Cancer Res Treat. 2009; 121(3):777-88. DOI: 10.1007/s10549-009-0560-5. View

Geisler S, Lonning P, Aas T, Johnsen H, Fluge O, Haugen D . Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001; 61(6):2505-12. View

Dobes P, Podhorec J, Coufal O, Jureckova A, Petrakova K, Vojtesek B . Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. Oncol Rep. 2014; 32(4):1695-702. DOI: 10.3892/or.2014.3346. View

Goldhirsch A, Winer E, Coates A, Gelber R, Piccart-Gebhart M, Thurlimann B . Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24(9):2206-23. PMC: 3755334. DOI: 10.1093/annonc/mdt303. View

Pare R, Soon P, Shah A, Lee C . Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients. PLoS One. 2019; 14(4):e0214604. PMC: 6472879. DOI: 10.1371/journal.pone.0214604. View

Cardoso F, Vant Veer L, Bogaerts J, Slaets L, Viale G, Delaloge S . 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375(8):717-29. DOI: 10.1056/NEJMoa1602253. View

Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J . The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006; 12(4):1157-67. DOI: 10.1158/1078-0432.CCR-05-1029. View

Kastenhuber E, Lowe S . Putting p53 in Context. Cell. 2017; 170(6):1062-1078. PMC: 5743327. DOI: 10.1016/j.cell.2017.08.028. View

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R . p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast. 2013; 22 Suppl 2:S27-9. DOI: 10.1016/j.breast.2013.07.005. View

10.

Duffy M, Synnott N, Crown J . Mutant p53 in breast cancer: potential as a therapeutic target and biomarker. Breast Cancer Res Treat. 2018; 170(2):213-219. DOI: 10.1007/s10549-018-4753-7. View

11.

Alsner J, Jensen V, Kyndi M, Offersen B, Vu P, Borresen-Dale A . A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol. 2008; 47(4):600-7. DOI: 10.1080/02841860802047411. View

12.

Lacroix M, Toillon R, Leclercq G . p53 and breast cancer, an update. Endocr Relat Cancer. 2006; 13(2):293-325. DOI: 10.1677/erc.1.01172. View

13.

Rahko E, Blanco G, Bloigu R, Soini Y, Talvensaari-Mattila A, Jukkola A . Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients-The role of p53. Breast. 2005; 15(1):69-75. DOI: 10.1016/j.breast.2005.04.004. View

14.

Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P . p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003; 11(3):577-90. DOI: 10.1016/s1097-2765(03)00050-9. View

15.

Walerych D, Napoli M, Collavin L, Del Sal G . The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012; 33(11):2007-17. PMC: 3483014. DOI: 10.1093/carcin/bgs232. View

16.

Dumay A, Feugeas J, Wittmer E, Lehmann-Che J, Bertheau P, Espie M . Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer. 2012; 132(5):1227-31. DOI: 10.1002/ijc.27767. View

17.

Ahn S, Kim H, Han W, Cho J, Gong G, Jung K . Effect Modification of Hormonal Therapy by p53 Status in Invasive Breast Cancer. J Breast Cancer. 2014; 16(4):386-94. PMC: 3893340. DOI: 10.4048/jbc.2013.16.4.386. View

18.

Norberg T, Lennerstrand J, Inganas M, Bergh J . Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer. 1998; 79(4):376-83. DOI: 10.1002/(sici)1097-0215(19980821)79:4<376::aid-ijc12>3.0.co;2-3. View

19.

Kikuchi S, Nishimura R, Osako T, Okumura Y, Nishiyama Y, Toyozumi Y . Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer. Anticancer Res. 2013; 33(9):3891-7. View

20.

Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D . Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015; 373(21):2005-14. PMC: 4701034. DOI: 10.1056/NEJMoa1510764. View